Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandamet Supply Issues Are Resolved, Allowing Launch Of New Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline's announcement about renewed Avandamet availability follows the approval of the type 2 diabetes drug for first-line use.

You may also be interested in...



Avandia Not Losing Market Share To Januvia, GSK Reports

Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.

Avandia Not Losing Market Share To Januvia, GSK Reports

Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.

Avandamet sNDA Approved For First-Line Use In Type 2 Diabetics

GlaxoSmithKline’s updated label for the rosiglitazone/metformin combination also includes new data concerning risk in congestive heart failure patients.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel